BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou S, Hill CS, Sarkar S, Tse LV, Woodburn BMD, Schinazi RF, Sheahan TP, Baric RS, Heise MT, Swanstrom R. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. J Infect Dis 2021;224:415-9. [PMID: 33961695 DOI: 10.1093/infdis/jiab247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Focosi D, Maggi F, Mcconnell S, Casadevall A. Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105247] [Reference Citation Analysis]
2 Brandsma I, Derr R, Zhang G, Moelijker N, Hendriks G, Østerlund T. Genotoxicity assessment of potentially mutagenic nucleoside analogues using ToxTracker®. Toxicology Letters 2022. [DOI: 10.1016/j.toxlet.2022.04.002] [Reference Citation Analysis]
3 Swanstrom R, Schinazi RF. Lethal mutagenesis as an antiviral strategy. Science 2022;375:497-8. [PMID: 35113690 DOI: 10.1126/science.abn0048] [Reference Citation Analysis]
4 Hashemian SMR, Pourhanifeh MH, Hamblin MR, Shahrzad MK, Mirzaei H. RdRp inhibitors and COVID-19: Is molnupiravir a good option? Biomed Pharmacother 2021;146:112517. [PMID: 34902743 DOI: 10.1016/j.biopha.2021.112517] [Reference Citation Analysis]
5 Tan S, Banwell MG, Ye WC, Lan P, White LV. The Inhibition of RNA Viruses by Amaryllidaceae Alkaloids: Opportunities for the Development of Broad-Spectrum Anti-Coronavirus Drugs. Chem Asian J 2022;:e202101215. [PMID: 35032358 DOI: 10.1002/asia.202101215] [Reference Citation Analysis]
6 Fan H, Lou F, Fan J, Li M, Tong Y. The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era. The Lancet Microbe 2021. [DOI: 10.1016/s2666-5247(21)00278-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shumaker AH, Bhimraj A. PHARMACOLOGIC TREATMENT AND MANAGEMENT OF COVID-19. Infectious Disease Clinics of North America 2022. [DOI: 10.1016/j.idc.2022.02.001] [Reference Citation Analysis]
8 Zhou S, Hill CS, Woodburn BMD, Schinazi RF, Swanstrom R. Reply to Troth et al. J Infect Dis 2021;224:1443-4. [PMID: 34255064 DOI: 10.1093/infdis/jiab363] [Reference Citation Analysis]
9 Yin J, Li C, Ye C, Ruan Z, Liang Y, Li Y, Wu J, Luo Z. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.01.026] [Reference Citation Analysis]
10 Fedeles BI, Li D, Singh V. Structural Insights Into Tautomeric Dynamics in Nucleic Acids and in Antiviral Nucleoside Analogs. Front Mol Biosci 2022;8:823253. [DOI: 10.3389/fmolb.2021.823253] [Reference Citation Analysis]
11 Wallace K, Bjork J. Molnupiravir; molecular and functional descriptors of mitochondrial safety. Toxicology and Applied Pharmacology 2022. [DOI: 10.1016/j.taap.2022.116003] [Reference Citation Analysis]
12 Stegmann KM, Dickmanns A, Heinen N, Blaurock C, Karrasch T, Breithaupt A, Klopfleisch R, Uhlig N, Eberlein V, Issmail L, Herrmann ST, Schreieck A, Peelen E, Kohlhof H, Sadeghi B, Riek A, Speakman JR, Groß U, Görlich D, Vitt D, Müller T, Grunwald T, Pfaender S, Balkema-Buschmann A, Dobbelstein M. Inhibitors of dihydroorotate dehydrogenase cooperate with Molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication. iScience 2022;:104293. [PMID: 35492218 DOI: 10.1016/j.isci.2022.104293] [Reference Citation Analysis]
13 Gandhi RT, Malani PN, Del Rio C. COVID-19 Therapeutics for Nonhospitalized Patients. JAMA 2022. [PMID: 35029659 DOI: 10.1001/jama.2022.0335] [Reference Citation Analysis]
14 Tian L, Pang Z, Li M, Lou F, An X, Zhu S, Song L, Tong Y, Fan H, Fan J. Molnupiravir and Its Antiviral Activity Against COVID-19. Front Immunol 2022;13:855496. [DOI: 10.3389/fimmu.2022.855496] [Reference Citation Analysis]
15 Anastassopoulou C, Hatziantoniou S, Boufidou F, Patrinos GP, Tsakris A. The Role of Oral Antivirals for COVID-19 Treatment in Shaping the Pandemic Landscape. JPM 2022;12:439. [DOI: 10.3390/jpm12030439] [Reference Citation Analysis]
16 Khiali S, Khani E, B Rouy S, Entezari-Maleki T. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic. Future Microbiol 2022. [PMID: 35199608 DOI: 10.2217/fmb-2021-0252] [Reference Citation Analysis]
17 Salasc F, Lahlali T, Laurent E, Rosa-Calatrava M, Pizzorno A. Treatments for COVID-19: Lessons from 2020 and new therapeutic options. Curr Opin Pharmacol 2021;62:43-59. [PMID: 34915400 DOI: 10.1016/j.coph.2021.11.002] [Reference Citation Analysis]
18 Sendi P, Razonable RR, Nelson SB, Soriano A, Gandhi RT. First-generation Oral Antivirals Against SARS-CoV-2. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.04.015] [Reference Citation Analysis]
19 Zhao L, Li S, Zhong W. Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review. Front Pharmacol 2022;13:840639. [DOI: 10.3389/fphar.2022.840639] [Reference Citation Analysis]
20 van Schalkwyk JM. Buyer beware: molnupiravir may damage DNA. BMJ 2021;375:n2663. [PMID: 34737196 DOI: 10.1136/bmj.n2663] [Reference Citation Analysis]
21 Hanna GS, Choo YM, Harbit R, Paeth H, Wilde S, Mackle J, Verga JU, Wolf BJ, Thomas OP, Croot P, Cray J, Thomas C, Li LZ, Hardiman G, Hu JF, Wang X, Patel D, Schinazi RF, O'Keefe BR, Hamann MT. Contemporary Approaches to the Discovery and Development of Broad-Spectrum Natural Product Prototypes for the Control of Coronaviruses. J Nat Prod 2021;84:3001-7. [PMID: 34677966 DOI: 10.1021/acs.jnatprod.1c00625] [Reference Citation Analysis]
22 Imran M, Kumar Arora M, Asdaq SMB, Khan SA, Alaqel SI, Alshammari MK, Alshehri MM, Alshrari AS, Mateq Ali A, Al-Shammeri AM, Alhazmi BD, Harshan AA, Alam MT, Abida. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. Molecules 2021;26:5795. [PMID: 34641339 DOI: 10.3390/molecules26195795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
23 Catlin N, Bowman C, Campion S, Cheung J, Nowland W, Sathish J, Stethem C, Updyke L, Cappon G. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models. Reproductive Toxicology 2022. [DOI: 10.1016/j.reprotox.2022.01.006] [Reference Citation Analysis]
24 Yoo JH. Antivirals for Coexistence with COVID-19: Brief Review for General Physicians. J Korean Med Sci 2021;36:e298. [PMID: 34725982 DOI: 10.3346/jkms.2021.36.e298] [Reference Citation Analysis]
25 Kunal S, Sakthivel P, Malhotra N, Ish P. Newer oral antivirals for COVID-19: are they the real game changer? Heart & Lung 2022. [DOI: 10.1016/j.hrtlng.2022.01.011] [Reference Citation Analysis]
26 Miguez-Rey E, Choi D, Kim S, Yoon S, Săndulescu O. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opin Investig Drugs 2022;:1-18. [PMID: 35164631 DOI: 10.1080/13543784.2022.2030310] [Reference Citation Analysis]
27 Hadj Hassine I, Ben M'hadheb M, Menéndez-Arias L. Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity. Viruses 2022;14:841. [PMID: 35458571 DOI: 10.3390/v14040841] [Reference Citation Analysis]
28 Troth S, Butterton J, DeAnda CS, Escobar P, Grobler J, Hazuda D, Painter G. Letter to the Editor in Response to Zhou et al. J Infect Dis 2021;224:1442-3. [PMID: 34251432 DOI: 10.1093/infdis/jiab362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Ledford H. COVID antiviral pills: what scientists still want to know. Nature 2021;599:358-9. [PMID: 34759341 DOI: 10.1038/d41586-021-03074-5] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Menéndez-Arias L. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2. J Biol Chem 2021;297:100867. [PMID: 34118236 DOI: 10.1016/j.jbc.2021.100867] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
31 Tarnawski AS, Ahluwalia A. Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs. World J Gastroenterol 2022;28:275-89. [PMID: 35110950 DOI: 10.3748/wjg.v28.i3.275] [Reference Citation Analysis]
32 Whitley R. Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-19. N Engl J Med 2021. [PMID: 34914869 DOI: 10.1056/NEJMe2117814] [Reference Citation Analysis]
33 Ng TI, Correia I, Seagal J, Degoey DA, Schrimpf MR, Hardee DJ, Noey EL, Kati WM. Antiviral Drug Discovery for the Treatment of COVID-19 Infections. Viruses 2022;14:961. [DOI: 10.3390/v14050961] [Reference Citation Analysis]
34 Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab Syndr 2021;15:102329. [PMID: 34742052 DOI: 10.1016/j.dsx.2021.102329] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Aydogdu MO, Rohn JL, Jafari NV, Brako F, Homer-Vanniasinkam S, Edirisinghe M. Severe Acute Respiratory Syndrome Type 2-Causing Coronavirus: Variants and Preventive Strategies. Adv Sci (Weinh) 2022;:e2104495. [PMID: 35037418 DOI: 10.1002/advs.202104495] [Reference Citation Analysis]
36 da Silva Torres MK, Bichara CDA, de Almeida MDNDS, Vallinoto MC, Queiroz MAF, Vallinoto IMVC, dos Santos EJM, de Carvalho CAM, Vallinoto ACR. The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. Front Microbiol 2022;13:789882. [DOI: 10.3389/fmicb.2022.789882] [Reference Citation Analysis]
37 Extance A. Covid-19: What is the evidence for the antiviral molnupiravir? BMJ 2022;377:o926. [PMID: 35418477 DOI: 10.1136/bmj.o926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem 2021;297:100770. [PMID: 33989635 DOI: 10.1016/j.jbc.2021.100770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
39 Zhao Y, He G, Huang W. A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe. Signal Transduct Target Ther 2021;6:410. [PMID: 34857753 DOI: 10.1038/s41392-021-00837-4] [Reference Citation Analysis]
40 Githaka JM. Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment. Bioinform Biol Insights 2022;16:11779322221085077. [PMID: 35342288 DOI: 10.1177/11779322221085077] [Reference Citation Analysis]
41 Ho WS, Zhang R, Tan YL, Chai CLL. COVID-19 and The Promise of Small Molecule Therapeutics: Are There Lessons to be Learnt? Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106201] [Reference Citation Analysis]
42 Cave JA, Phizackerley D. Molnupiravir: evidence by press release. Drug Ther Bull 2022;60:2. [PMID: 34893500 DOI: 10.1136/dtb.2021.000064] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Calleja DJ, Lessene G, Komander D. Inhibitors of SARS-CoV-2 PLpro. Front Chem 2022;10:876212. [DOI: 10.3389/fchem.2022.876212] [Reference Citation Analysis]
44 Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, Wang M, Mao Q. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann Med 2022;54:516-23. [PMID: 35118917 DOI: 10.1080/07853890.2022.2034936] [Reference Citation Analysis]
45 Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW. SARS-CoV-2 Antiviral Therapy. Clin Microbiol Rev 2021;:e0010921. [PMID: 34319150 DOI: 10.1128/CMR.00109-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 White JM, Schiffer JT, Bender Ignacio RA, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ, Prasad VR. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio 2021;12:e03347-21. [DOI: 10.1128/mbio.03347-21] [Reference Citation Analysis]
47 Kamal L, Ramadan A, Farraj S, Bahig L, Ezzat S. The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review. Saudi Pharmaceutical Journal 2022. [DOI: 10.1016/j.jsps.2022.03.002] [Reference Citation Analysis]